Author: Bénard, Alan; Jacobsen, Anne; Brunner, Maximilian; Krautz, Christian; Klösch, Bettina; Swierzy, Izabela; Naschberger, Elisabeth; Podolska, Malgorzata J.; Kouhestani, Dina; David, Paul; Birkholz, Torsten; Castellanos, Ixchel; Trufa, Denis; Sirbu, Horia; Vetter, Marcel; Kremer, Andreas E.; Hildner, Kai; Hecker, Andreas; Edinger, Fabian; Tenbusch, Matthias; Mühl-Zürbes, Petra; Steinkasserer, Alexander; Richter, Enrico; Streeck, Hendrik; Berger, Marc M.; Brenner, Thorsten; Weigand, Markus A.; Swirski, Filip K.; Schett, Georg; Grützmann, Robert; Weber, Georg F.
Title: Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections Cord-id: 7a7ike28 Document date: 2021_2_18
ID: 7a7ike28
Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. In a prospective multicentric study, we identify IL-3 as an independent prognostic marker for the outcome during SARS-CoV-2 infections. Specifically, low plasma IL-3 levels is associated with increased severity, viral load, and mortality during SARS-CoV-2 infections. Patients with severe COVID-19 exhibit also reduced circulating plasmacytoid dendritic cells (pDCs) and low plasma IFNα and IFNλ levels when
Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. In a prospective multicentric study, we identify IL-3 as an independent prognostic marker for the outcome during SARS-CoV-2 infections. Specifically, low plasma IL-3 levels is associated with increased severity, viral load, and mortality during SARS-CoV-2 infections. Patients with severe COVID-19 exhibit also reduced circulating plasmacytoid dendritic cells (pDCs) and low plasma IFNα and IFNλ levels when compared to non-severe COVID-19 patients. In a mouse model of pulmonary HSV-1 infection, treatment with recombinant IL-3 reduces viral load and mortality. Mechanistically, IL-3 increases innate antiviral immunity by promoting the recruitment of circulating pDCs into the airways by stimulating CXCL12 secretion from pulmonary CD123(+) epithelial cells, both, in mice and in COVID-19 negative patients exhibiting pulmonary diseases. This study identifies IL-3 as a predictive disease marker for SARS-CoV-2 infections and as a potential therapeutic target for pulmunory viral infections.
Search related documents:
Co phrase search for related documents- active replication and lung injury: 1
- active replication and lung tissue: 1, 2, 3
- acute inflammation and adaptive immune cell: 1, 2
- acute inflammation and low mortality: 1, 2, 3
- acute inflammation and low mortality rate: 1
- acute inflammation and low plasma: 1, 2
- acute inflammation and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute inflammation and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute inflammation and lung injury ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute inflammation and lung parenchyma: 1, 2, 3, 4, 5
- acute inflammation and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- ad libitum and lung damage: 1
- ad libitum and lung injury: 1, 2
Co phrase search for related documents, hyperlinks ordered by date